Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dawei Wu

Showing results (211-220 of 247) with videos related to

Pageof 25
Sort By:
Infection and Drug Resistance|September 27, 2021
High-Dose versus Standard-Dose Tigecycline Treatment of Secondary Bloodstream Infections Caused by Extensively Drug-Resistant <i>Acinetobacter baumannii</i>: An Observational Cohort StudyHui Han, Weidong Qin, Yue Zheng, et al.
BMC Geriatrics|March 30, 2023
Unfair older patients restriction in cancer drug trials in mainland China and corresponding solutionHuiyao Huang, Yu Tang, Dawei Wu, et al.
Biochemical and Biophysical Research Communications|March 26, 2021
Tubular epithelial cells derived-exosomes containing CD26 protects mice against renal ischemia/reperfusion injury by maintaining proliferation and dissipating inflammationJuan Du, Qiang Sun, Zhihao Wang, et al.
Asia-Pacific Journal of Oncology Nursing|October 31, 2022
Consensus on informed consent for participants in cancer clinical studies (2021 edition)Dawei Wu, Meimei Chen, Jing Liang, et al.
Frontiers in Immunology|September 30, 2022
Association between germ-line HLA and immune-related adverse eventsNing Jiang, Yue Yu, Min Zhang, et al.
British Journal of Cancer|May 15, 2018
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 studyHongnan Mo, Jing Huang, Jiachen Xu, et al.
ACS Nano|January 18, 2025
Efficient Nitrate to Ammonia Conversion on Bifunctional IrCu<sub>4</sub> Alloy NanoparticlesNing He, Zhi Yuan, Chao Wu, et al.
The Lancet. Oncology|November 3, 2022
Accelerating the integration of China into the global development of innovative anticancer drugsHuiyao Huang, Dawei Wu, Huilei Miao, et al.
Science Advances|June 19, 2026
Synchronous wearable ultrasound for early detection of coronary and carotid artery comorbidityShengrong Lin, Hao Xu, Ya Li, et al.
Journal for Immunotherapy of Cancer|April 10, 2021
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trialBo Zhang, Jing Huang, Jialin Tang, et al.
Pageof 25

Showing results (211-220 of 247) with videos related to

Sort By:
Pageof 25
Infection and Drug Resistance|September 27, 2021
High-Dose versus Standard-Dose Tigecycline Treatment of Secondary Bloodstream Infections Caused by Extensively Drug-Resistant <i>Acinetobacter baumannii</i>: An Observational Cohort StudyHui Han, Weidong Qin, Yue Zheng, et al.
BMC Geriatrics|March 30, 2023
Unfair older patients restriction in cancer drug trials in mainland China and corresponding solutionHuiyao Huang, Yu Tang, Dawei Wu, et al.
Biochemical and Biophysical Research Communications|March 26, 2021
Tubular epithelial cells derived-exosomes containing CD26 protects mice against renal ischemia/reperfusion injury by maintaining proliferation and dissipating inflammationJuan Du, Qiang Sun, Zhihao Wang, et al.
Asia-Pacific Journal of Oncology Nursing|October 31, 2022
Consensus on informed consent for participants in cancer clinical studies (2021 edition)Dawei Wu, Meimei Chen, Jing Liang, et al.
Frontiers in Immunology|September 30, 2022
Association between germ-line HLA and immune-related adverse eventsNing Jiang, Yue Yu, Min Zhang, et al.
British Journal of Cancer|May 15, 2018
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 studyHongnan Mo, Jing Huang, Jiachen Xu, et al.
ACS Nano|January 18, 2025
Efficient Nitrate to Ammonia Conversion on Bifunctional IrCu<sub>4</sub> Alloy NanoparticlesNing He, Zhi Yuan, Chao Wu, et al.
The Lancet. Oncology|November 3, 2022
Accelerating the integration of China into the global development of innovative anticancer drugsHuiyao Huang, Dawei Wu, Huilei Miao, et al.
Science Advances|June 19, 2026
Synchronous wearable ultrasound for early detection of coronary and carotid artery comorbidityShengrong Lin, Hao Xu, Ya Li, et al.
Journal for Immunotherapy of Cancer|April 10, 2021
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trialBo Zhang, Jing Huang, Jialin Tang, et al.
Pageof 25